Alex Szidon, Head of Business Development Genentech Research & Early Development, Pharma Partnering - Roche and Genentech Company Presentation
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Roche and Genentech Company Presentation Alex Szidon, Head of Business Development Genentech Research & Early Development, Pharma Partnering June 2020
The Roche Group: an Why we make a What we are looking
innovation-led company good partner for from you
2
The Roche Group
A leading healthcare company dedicated to innovation in a sustainable way
1896 61.5 bn
Genentech1, first
publicly-owned
Founded in Basel
Family still holds
majority stake
Sales 2019 (CHF)
Biotech
♯1 97’735 63,000,000
people treated
R&D investor in Employees worldwide
worldwide with our
healthcare
medicines in 2019
Lasting… … and Sustainable 31
>30 medicines
on World Health Among top companies in Dow Jones FDA Breakthrough
Organization List of Sustainability Index (Life Sciences Sector) Designations
Essential Medicines for 10 consecutive years
1 Genentech became a full member of the Roche group in March 2009 3
The leader in personalized healthcare
Optimally positioning us for the future
Combining
pharmaceuticals and
diagnostics under one roof
together with deep know-how
in molecular biology and data
science, make Roche a
unique partner to drive next
step in the evolution
of healthcare.
Leader in Diagnostics Leader in Pharma
Diagnosis Decision Support Therapy Therapy monitoring 4
The Roche Group: an What we are looking
innovation-led company Why we make a for from you
good partner
5
Active partnerships across the globe
Over 220 partnerships across North America, Europe and Asia Pacific
Europe
26%
59% 15%
Asia Pacific
North America
6
Our approach to Partnering in the Pharma industry
We value external innovation and bring our best experts to the table
7
Because a great idea is a great idea…
…no matter where it comes from
∼ 50% ∼ 40%
of R&D pipeline of total Pharma sales
involve a partnership generated from partnered
or in-licensed products
8
Roche launched 16 new molecules since 2011
11 out of the 16 are partnered medicines
2011 2012 2013 2014 2015 2016 2017 2018 2019
Partnered medicines 9
We believe in flexibility of deal structures
Tailored for mutual value and partners’ wants and needs
Option Deal
Buyer Licensing Seller
Co-development
Earn-out
M&A
10The Roche Group: an Why we make a
innovation-led company good partner What we are looking
for from you
11What we are looking for in a partnering opportunity
Innovative science with the potential to make a significant
difference for patients
What we are focusing on What we don’t do What we are looking for
Clear connection between
High disease burden Generics, biosimilars
MoA and pathobiology
Novel targets OTCs Robust data linking
MoA, PK and PD
Potential for first- or best-in Animal Health Biomarker strategy
class molecules
Novel enabling modalities
12Our focus areas
Seeking great science across multiple therapeutic areas
Oncology & Cancer Immunology & Neuroscience, Research Technologies Digital & Personalized
Immunotherapy Infectious Diseases Ophthalmology & Healthcare
Rare Diseases
Oncogenic drivers GI, Respiratory, Neurodegeneration Technologies & modalities Robust data sets
Rheumatology enabling challenging
Synthetic lethality Neuroinflammation Advanced Analytics (AI
• Innate, Adaptive, targets
incl. Machine learning
Adaptive and Innate Fibrosis, Tolerance and Neurodevelopmental
Targeted delivery / and deep learning
immunity Tissue Regeneration intracellular delivery models)
Targets Pain (non-opioid treatments
Neoantigens for chronic pain)
AI for drug discovery Digital and mobile
Hep B & Respiratory technologies
Stromal biology Viruses Retinal diseases and dry eye
Genomic medicine
disease
approaches
Cell therapies MDR Gram (-) Infections
Monogenetic rare diseases
Ocular delivery
13Roche Pharma Partnering
NEUROSCIENCE, IMMUNOLOGY, RESEARCH ALLIANCE &
OPHTHALMOLOGY INFECTIOUS DISEASE TECHNOLOGIES ASSET MANAGEMENT
& RARE DISEASES & SPECIALTY CARE
Barbara Lueckel Urs Schleuniger
Tom Zioncheck Pat Schleck Phone: +41 79 264 3944 Phone: +41 61 687 7842
Phone: +41 61 682 17 78 Phone: +1 973 420 4497 Email: barbara.lueckel@roche.com Email: urs.schleuniger@roche.com
Email: tom.zioncheck@roche.com Email: schleckp@gene.com
Mark Schiebler
J.C. Lopez Karl Yen Phone: +41 79 361 1421 R&D OUT-PARTNERING
Phone: +1 650 467 1877 Phone: +41 79 573 61 24 Email: mark.schiebler@roche.com
Email: lopez.julio@gene.com Email: karl.yen@roche.com Joerg Kazenwadel
Phone: + 41 61 687 0524
Email: joerg.kazenwadel@roche.com
ONCOLOGY DIGITAL & ASIA
& CANCER PERSONALIZED Japan and Korea
IMMUNOTHERAPY HEALTHCARE COMMUNICATIONS
Kaoru Suzuki
Don O’Sullivan Gregg Talbert Phone: +81 3 6743 4237 Tiffany Payette
Phone: +1 650 225 4405 Phone: +1 650 225 6405 Email: kaoru.suzuki@roche.com Phone: +41 79 644 41 60
Email: osullivan.don@gene.com Email: talbert.gregg@gene.com Email: tiffany.payette@roche.com
China, Taiwan & Singapore
Danielle Bittencourt Erika Pollex
Phone: +1 650 467 8411 Phone: +1 650 303-4960 Yingjie Wu
Email: bittencourt.danielle@gene.com Email: pollexe@gene.com Phone: +86 21 2894 6153
Email: yingjie.wu@roche.com
14Doing now what patients need next
15You can also read
